Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy
Author:
Irelli Azzurra1ORCID, Chiatamone Ranieri Sofia2ORCID, Di Giacomo Daniela2, Malatesta Sara2, Patruno Leonardo Valerio1, Tessitore Alessandra3, Alesse Edoardo3, Cannita Katia1
Affiliation:
1. Medical Oncology Unit, Department of Oncology, AUSL 04 Teramo, 64100 Teramo, Italy 2. Pathology Unit, Department of Services, AUSL 04 Teramo, 64100 Teramo, Italy 3. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, 67100 L’Aquila, Italy
Abstract
Molecular tumor boards (MTBs) are multidisciplinary groups that combine molecular and clinical data from cancer patients in order to formulate treatment recommendations for precision medicine. To date, there is insufficient data to support the use of singleplex or next-generation sequencing (NGS) technologies to select first-line therapy for patients with metastatic breast cancer (MBC), but considering the high number of level II alterations, according to the ESMO scale for clinical actionability of molecular targets (ESCAT), it is suggested to include patients in molecular screening programs in order to be able to offer targeted therapies for specific genomic alterations. This article aims at reviewing the most recent literature related to the most used methodologies/approaches for molecular diagnostics and variants’ classification, summarizing the internationally published molecular screening studies in support of MTB activity and, in the end, discussing MTBs’ current position and role in Italy, the number of which is increasing, also thanks to the thrust of institutions.
Subject
Cancer Research,Oncology
Reference60 articles.
1. Di Pilla, A., Cozzolino, M.R., Mannocci, A., Carini, E., Spina, F., Castrini, F., Grieco, A., Messina, R., Damiani, G., and Specchia, M.L. (2022). The Impact of Tumor Boards on Breast Cancer Care: Evidence from a Systematic Literature Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 19. 2. Gori, S., Miglietta, F., and Modena, A. (2021). Mammella. I numeri del cancro in Italia, Intermedia Editore. Available online: https://www.aiom.it/wp-content/uploads/2021/11/2021_NDC.pdf. 3. Gori, S., Miglietta, F., Biganzoli, L., Calabrese, M., Cortesi, L., Conte, B., Criscitiello, C., Del Mastro, L., Dieci, M.V., and Folli, S. (2021). Linee guida “Neoplasie della mammella”, Associazione Italiana di Oncologia Medica. Available online: https://www.aiom.it/wp-content/uploads/2021/11/2021_LG_AIOM_Neoplasie_Mammella_11112021.pdf.pdf. 4. The requirements of a specialist breast centre;Biganzoli;Breast,2020 5. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann. Oncol.,2021
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|